Compare Medpace Holdings Inc (MEDP) vs ArcelorMittal SA (MT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs ArcelorMittal SA — how do they compare? Medpace Holdings Inc trades at $531.09 (market cap $15.08B), while ArcelorMittal SA trades at $65.52 (market cap $50.01B). The key difference: ArcelorMittal SA is far larger — about 3.3× Medpace Holdings Inc's market cap, and ArcelorMittal SA pays a 0.91% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | MT | |
|---|---|---|
Market Cap | $15.08B | $50.01B |
Sector | Technology | Basic Materials |
52-Week High | $620.59 | $71.65 |
52-Week Low | $308.88 | $30.39 |
Enterprise Value | $14.55B | $59.33B |
Dividend Yield | — | 0.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
ArcelorMittal (MT) trades at $65.81, down 0.96% on the day but remains near its 52-week high of $72.50. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent developments include a strategic AI collaboration with AWS and ongoing share buybacks, while analyst sentiment is mixed with 50% recommending Buy.
Outlook: MT presents value with attractive P/E (17.4) and P/B (0.91) ratios, supported by rising net margins. Risks include declining revenue trends, high capital expenditures, and exposure to steel market volatility. The stock's upside depends on execution of expansion projects and stable commodity pricing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About ArcelorMittal SA
ArcelorMittal SA is involved in the steel industry. The company's operating segments include NAFTA
Read more on MT →
